Coverage of Prandial Insulin Requirements: An Elusive Goal

Heinemann L , Heise T , Wahl Ch , et al.: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)]. Diabet Med, 1996; 13:625–629.

Heinemann L , Muchmore DB : Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol, 2012; 6:728–742.

Luijf YM , van Bon AC , Hoekstra JB , DeVries JH : Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care, 2010; 33:2152–2155.

Cobry E , McFann K , Messer L , et al.: Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther, 2010; 12:173–177.

Heinemann L , Baughman R , Boss A , Hompesch M : Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2016. [Epub ahead of print]; DOI: 1932296816658055.

Muchmore DB : The need for faster insulin: problem solved?. J Diabetes Sci Technol, 2016. [Epub ahead of print]; DOI: 10.1177/193229681667757.

Russel-Jones DL , Bode B , De Block C , et al.: Double-blind mealtime faster-acting insulin aspart vs. isulin aspart in basal-bolus improves glycemic control in T1D: the Onset® 1 trial. Can J Diabetes, 2016; 40 (Suppl). DOI: 10.1016/j.jcjd.2016.08.162.

Bode BW , Johnson JA , Hyveled L , et al.: Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using continuous sucutaneous insulin infusion. Diabetes Technol Ther, 2017; 19:25–33.

Andersen G , Meiffren G , Alluis B , et al.: Ultra-rapid BioChaperone lispro ameliorates postprandial blood glucose control compared to insulin lispro commercial formulation in subjects with type 1 diabetes mellitus. Diabetologia, 2016; 59 (Suppl):S5.